P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000845956.26644.d0 |
| _version_ | 1797281779712786432 |
|---|---|
| author | G. Garcia-Manero S. Bart J. K. McCloskey P. Fenaux D. Selleslag G. Reda D. Valcárcel V. Santini J. Mayer B. Xicoy H. Yamaguchi M. Lübbert Y. Miyazaki H. Keer Y. Hao M. Azab H. Döhner |
| author_facet | G. Garcia-Manero S. Bart J. K. McCloskey P. Fenaux D. Selleslag G. Reda D. Valcárcel V. Santini J. Mayer B. Xicoy H. Yamaguchi M. Lübbert Y. Miyazaki H. Keer Y. Hao M. Azab H. Döhner |
| author_sort | G. Garcia-Manero |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:02:22Z |
| format | Article |
| id | doaj.art-e22abb107df64da2a5b1fcbcdbe749e9 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:02:22Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-e22abb107df64da2a5b1fcbcdbe749e92024-03-03T03:19:42ZengWileyHemaSphere2572-92412022-06-01666366410.1097/01.HS9.0000845956.26644.d0202206003-00663P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY.G. Garcia-Manero0S. Bart1J. K. McCloskey2P. Fenaux3D. Selleslag4G. Reda5D. Valcárcel6V. Santini7J. Mayer8B. Xicoy9H. Yamaguchi10M. Lübbert11Y. Miyazaki12H. Keer13Y. Hao14M. Azab15H. Döhner161 The University of Texas MD Anderson Cancer Center, Houston2 Fred Hutchinson Cancer Research Center, Seattle3 John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, United States of America4 Hôpital Saint Louis, Paris, France5 Algemeen Ziekenhuis Sint-Jan Brugge-Oostende, Brugge, Belgium6 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy7 Hospital Universitari Vall d’Hebrón, Barcelona, Spain8 MDS Unit AOU Careggi, DMSC University of Florence, Florence, Italy9 Fakultní Nemocnice Brno, Brno, Czechia10 Institut Català d’Oncologia-Hospital Universitari Germans Trias i Pujol, Badalona, Spain11 Nippon Medical School Hospital, Tokyo, Japan12 Universitaetsklinikum Freiburg, Freiburg, Germany13 Nagasaki University Hospital, Nagasaki, Japan14 Astex Pharmaceuticals, Inc., Pleasanton, United States of America14 Astex Pharmaceuticals, Inc., Pleasanton, United States of America14 Astex Pharmaceuticals, Inc., Pleasanton, United States of America15 Ulm University Hospital, Ulm, Germanyhttp://journals.lww.com/10.1097/01.HS9.0000845956.26644.d0 |
| spellingShingle | G. Garcia-Manero S. Bart J. K. McCloskey P. Fenaux D. Selleslag G. Reda D. Valcárcel V. Santini J. Mayer B. Xicoy H. Yamaguchi M. Lübbert Y. Miyazaki H. Keer Y. Hao M. Azab H. Döhner P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. HemaSphere |
| title | P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. |
| title_full | P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. |
| title_fullStr | P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. |
| title_full_unstemmed | P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. |
| title_short | P768: GUADECITABINE (SGI-110) VS. TREATMENT CHOICE (TC) IN RELAPSED/REFRACTORY(R/R) MYELODYSPLASTIC SYNDROME (MDS), RESULTS OF A GLOBAL, RANDOMIZED, PHASE 3 STUDY. |
| title_sort | p768 guadecitabine sgi 110 vs treatment choice tc in relapsed refractory r r myelodysplastic syndrome mds results of a global randomized phase 3 study |
| url | http://journals.lww.com/10.1097/01.HS9.0000845956.26644.d0 |
| work_keys_str_mv | AT ggarciamanero p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT sbart p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT jkmccloskey p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT pfenaux p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT dselleslag p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT greda p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT dvalcarcel p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT vsantini p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT jmayer p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT bxicoy p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT hyamaguchi p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT mlubbert p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT ymiyazaki p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT hkeer p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT yhao p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT mazab p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study AT hdohner p768guadecitabinesgi110vstreatmentchoicetcinrelapsedrefractoryrrmyelodysplasticsyndromemdsresultsofaglobalrandomizedphase3study |